• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023

    5/23/23 11:00:41 AM ET
    $AXNX
    $BLD
    $CCCS
    $CLF
    Medical/Dental Instruments
    Health Care
    Engineering & Construction
    Consumer Discretionary
    Get the next $AXNX alert in real time by email

    Upgrades

    MoffettNathanson upgraded the previous rating for Zoom Video Communications Inc (NASDAQ:ZM) from Underperform to Market Perform. Zoom Video Comms earned $1.16 in the first quarter, compared to $1.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $124.05 and a 52-week-low of $60.45. Zoom Video Comms closed at $71.41 at the end of the last trading period.

    Evercore ISI Group upgraded the previous rating for CCC Intelligent Solutions Holdings Inc (NASDAQ:CCCS) from In-Line to Outperform. For the first quarter, CCC Intelligent Solutions had an EPS of $0.07, compared to year-ago quarter EPS of $0.08. The current stock performance of CCC Intelligent Solutions shows a 52-week-high of $10.19 and a 52-week-low of $8.20. Moreover, at the end of the last trading period, the closing price was at $9.92.

    According to HSBC, the prior rating for Chevron Corp (NYSE:CVX) was changed from Hold to Buy. For the first quarter, Chevron had an EPS of $3.55, compared to year-ago quarter EPS of $3.36. At the moment, the stock has a 52-week-high of $189.66 and a 52-week-low of $132.54. Chevron closed at $152.44 at the end of the last trading period.

    According to Goldman Sachs, the prior rating for Quanterix Corp (NASDAQ:QTRX) was changed from Neutral to Buy. For the first quarter, Quanterix had an EPS of $0.16, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $20.20 and a 52-week-low of $6.32. Quanterix closed at $19.23 at the end of the last trading period.

    For Myriad Genetics Inc (NASDAQ:MYGN), Goldman Sachs upgraded the previous rating of Sell to Buy. Myriad Genetics earned $0.21 in the first quarter, compared to $0.03 in the year-ago quarter. The stock has a 52-week-high of $28.17 and a 52-week-low of $13.92. At the end of the last trading period, Myriad Genetics closed at $20.07.

    For Greenhill & Co Inc (NYSE:GHL), Keefe, Bruyette & Woods upgraded the previous rating of Underperform to Market Perform. Greenhill & Co earned $1.27 in the first quarter, compared to $0.66 in the year-ago quarter. The current stock performance of Greenhill & Co shows a 52-week-high of $14.85 and a 52-week-low of $5.70. Moreover, at the end of the last trading period, the closing price was at $14.66.

    See all analyst ratings upgrades.

    Downgrades

    For Rain Oncology Inc (NASDAQ:RAIN), Citigroup downgraded the previous rating of Buy to Neutral. Rain Oncology earned $0.56 in the first quarter, compared to $0.66 in the year-ago quarter. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

    Citigroup downgraded the previous rating for Integra Lifesciences Holdings Corp (NASDAQ:IART) from Neutral to Sell. For the first quarter, Integra Lifesciences had an EPS of $0.74, compared to year-ago quarter EPS of $0.74. The stock has a 52-week-high of $62.94 and a 52-week-low of $40.68. At the end of the last trading period, Integra Lifesciences closed at $50.72.

    Piper Sandler downgraded the previous rating for VectivBio Holding AG (NASDAQ:VECT) from Overweight to Neutral. None

    For VectivBio Holding AG (NASDAQ:VECT), SVB Leerink downgraded the previous rating of Outperform to Market Perform. None

    For Maravai LifeSciences Holdings Inc (NASDAQ:MRVI), Credit Suisse downgraded the previous rating of Outperform to Neutral. In the first quarter, Maravai LifeSciences showed an EPS of $0.03, compared to $0.54 from the year-ago quarter. The current stock performance of Maravai LifeSciences shows a 52-week-high of $35.82 and a 52-week-low of $11.89. Moreover, at the end of the last trading period, the closing price was at $13.60.

    According to Needham, the prior rating for Intercept Pharmaceuticals Inc (NASDAQ:ICPT) was changed from Buy to Hold. For the first quarter, Intercept Pharma had an EPS of $0.77, compared to year-ago quarter EPS of $0.58. The stock has a 52-week-high of $21.86 and a 52-week-low of $9.21. At the end of the last trading period, Intercept Pharma closed at $9.53.

    RBC Capital downgraded the previous rating for Wheaton Precious Metals Corp (NYSE:WPM) from Outperform to Sector Perform. In the first quarter, Wheaton Precious Metals showed an EPS of $0.23, compared to $0.35 from the year-ago quarter. The stock has a 52-week-high of $52.76 and a 52-week-low of $28.63. At the end of the last trading period, Wheaton Precious Metals closed at $47.79.

    JonesTrading downgraded the previous rating for Rain Oncology Inc (NASDAQ:RAIN) from Buy to Hold. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

    For Rain Oncology Inc (NASDAQ:RAIN), HC Wainwright & Co. downgraded the previous rating of Buy to Neutral. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

    Piper Sandler downgraded the previous rating for Rain Oncology Inc (NASDAQ:RAIN) from Overweight to Neutral. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. The current stock performance of Rain Oncology shows a 52-week-high of $14.48 and a 52-week-low of $1.11. Moreover, at the end of the last trading period, the closing price was at $1.22.

    JMP Securities downgraded the previous rating for Greenhill & Co Inc (NYSE:GHL) from Market Outperform to Market Perform. For the first quarter, Greenhill & Co had an EPS of $1.27, compared to year-ago quarter EPS of $0.66. The current stock performance of Greenhill & Co shows a 52-week-high of $14.85 and a 52-week-low of $5.70. Moreover, at the end of the last trading period, the closing price was at $14.66.

    According to Oppenheimer, the prior rating for Rain Oncology Inc (NASDAQ:RAIN) was changed from Outperform to Perform. In the first quarter, Rain Oncology showed an EPS of $0.56, compared to $0.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. Rain Oncology closed at $1.22 at the end of the last trading period.

    For Rain Oncology Inc (NASDAQ:RAIN), EF Hutton downgraded the previous rating of Buy to Hold. For the first quarter, Rain Oncology had an EPS of $0.56, compared to year-ago quarter EPS of $0.66. The stock has a 52-week-high of $14.48 and a 52-week-low of $1.11. At the end of the last trading period, Rain Oncology closed at $1.22.

    Credit Suisse downgraded the previous rating for VectivBio Holding AG (NASDAQ:VECT) from Outperform to Neutral. None

    See all analyst ratings downgrades.

    Initiations

    JP Morgan initiated coverage on United States Steel Corp (NYSE:X) with a Neutral rating. The price target for United States Steel is set to $24.00. United States Steel earned $0.77 in the first quarter, compared to $3.05 in the year-ago quarter. The stock has a 52-week-high of $31.55 and a 52-week-low of $16.42. At the end of the last trading period, United States Steel closed at $21.70.

    For Precigen Inc (NASDAQ:PGEN), JP Morgan initiated coverage, by setting the current rating at Neutral. In the first quarter, Precigen showed an EPS of $0.10, compared to $0.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of $2.90 and a 52-week-low of $0.81. Precigen closed at $1.31 at the end of the last trading period.

    With a Buy rating, CL King initiated coverage on Silk Road Medical Inc (NASDAQ:SILK). The price target seems to have been set at $47.00 for Silk Road Medical. For the first quarter, Silk Road Medical had an EPS of $0.43, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of $58.04 and a 52-week-low of $27.45. Silk Road Medical closed at $31.46 at the end of the last trading period.

    JP Morgan initiated coverage on GrafTech International Ltd (NYSE:EAF) with a Neutral rating. For the first quarter, GrafTech International had an EPS of $0.02, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of $9.27 and a 52-week-low of $3.75. GrafTech International closed at $4.57 at the end of the last trading period.

    With a Buy rating, CL King initiated coverage on Axonics Inc (NASDAQ:AXNX). The price target seems to have been set at $75.00 for Axonics. In the first quarter, Axonics showed an EPS of $0.19, compared to $0.50 from the year-ago quarter. At the moment, the stock has a 52-week-high of $79.88 and a 52-week-low of $47.30. Axonics closed at $51.61 at the end of the last trading period.

    With a Buy rating, B of A Securities initiated coverage on TopBuild Corp (NYSE:BLD). The price target seems to have been set at $225.00 for TopBuild. TopBuild earned $4.36 in the first quarter, compared to $3.50 in the year-ago quarter. The current stock performance of TopBuild shows a 52-week-high of $227.08 and a 52-week-low of $140.93. Moreover, at the end of the last trading period, the closing price was at $209.72.

    JP Morgan initiated coverage on Steel Dynamics Inc (NASDAQ:STLD) with an Underweight rating. The price target for Steel Dynamics is set to $82.00. For the first quarter, Steel Dynamics had an EPS of $4.01, compared to year-ago quarter EPS of $6.02. The current stock performance of Steel Dynamics shows a 52-week-high of $136.46 and a 52-week-low of $62.44. Moreover, at the end of the last trading period, the closing price was at $97.19.

    With an Underweight rating, JP Morgan initiated coverage on Nucor Corp (NYSE:NUE). The price target seems to have been set at $130.00 for Nucor. For the first quarter, Nucor had an EPS of $4.45, compared to year-ago quarter EPS of $7.67. The stock has a 52-week-high of $182.68 and a 52-week-low of $100.15. At the end of the last trading period, Nucor closed at $139.96.

    With a Neutral rating, JP Morgan initiated coverage on Cleveland-Cliffs Inc (NYSE:CLF). The price target seems to have been set at $18.00 for Cleveland-Cliffs. Cleveland-Cliffs earned $0.11 in the first quarter, compared to $1.71 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.65 and a 52-week-low of $11.82. Cleveland-Cliffs closed at $14.87 at the end of the last trading period.

    Baird initiated coverage on Chimerix Inc (NASDAQ:CMRX) with an Outperform rating. The price target for Chimerix is set to $7.00. Chimerix earned $0.24 in the first quarter, compared to $0.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of $2.89 and a 52-week-low of $1.09. Chimerix closed at $1.40 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $AXNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXNX
    $BLD
    $CCCS
    $CLF

    CompanyDatePrice TargetRatingAnalyst
    Zoom Communications Inc.
    $ZM
    2/5/2026$115.00Peer Perform → Outperform
    Wolfe Research
    Chevron Corporation
    $CVX
    2/2/2026$160.00 → $168.00Hold
    TD Cowen
    Chevron Corporation
    $CVX
    2/2/2026$180.00Buy → Hold
    HSBC Securities
    Nucor Corporation
    $NUE
    1/28/2026$183.00Buy → Neutral
    UBS
    Cleveland-Cliffs Inc.
    $CLF
    1/23/2026Buy → Neutral
    Seaport Research Partners
    Chevron Corporation
    $CVX
    1/20/2026$176.00Neutral → Overweight
    Analyst
    Zoom Communications Inc.
    $ZM
    1/12/2026$106.00Neutral → Buy
    Citigroup
    Steel Dynamics Inc.
    $STLD
    1/9/2026$194.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $AXNX
    $BLD
    $CCCS
    $CLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, President & CEO Goncalves Lourenco sold $37,257,300 worth of shares (3,000,000 units at $12.42) (SEC Form 4)

    4 - CLEVELAND-CLIFFS INC. (0000764065) (Issuer)

    2/11/26 6:52:03 PM ET
    $CLF
    Metal Mining
    Basic Materials

    Director Subotovsky Santiago sold $223,716 worth of shares (2,475 units at $90.39), decreasing direct ownership by 2% to 155,917 units (SEC Form 4)

    4 - Zoom Communications, Inc. (0001585521) (Issuer)

    2/9/26 5:30:23 PM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    Chief Financial Officer Sriram Vandana covered exercise/tax liability with 4,395 shares, decreasing direct ownership by 5% to 81,618 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    2/6/26 6:58:51 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AXNX
    $BLD
    $CCCS
    $CLF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoom Communications upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Zoom Communications from Peer Perform to Outperform and set a new price target of $115.00

    2/5/26 6:52:31 AM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    TD Cowen reiterated coverage on Chevron with a new price target

    TD Cowen reiterated coverage of Chevron with a rating of Hold and set a new price target of $168.00 from $160.00 previously

    2/2/26 7:18:00 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Chevron downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Chevron from Buy to Hold and set a new price target of $180.00

    2/2/26 6:48:45 AM ET
    $CVX
    Integrated oil Companies
    Energy

    $AXNX
    $BLD
    $CCCS
    $CLF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chevron Enters Libya With New Block Award as Part of Broader Exploration Growth Strategy

    Chevron Corporation (NYSE:CVX) by its subsidiary Chevron Business Development EMEA Ltd., has entered Libya after it was designated as a winning bidder in the 2025 Libyan Bid Round. This follows the signing of a Memorandum of Understanding (MoU) with the country's National Oil Corporation (NOC). Chevron was designated as the winning bidder for Contract Area 106 located in the Sirte Basin on February 11, 2026 in Libya's 2025 Bidding Round. On January 24, 2026 Chevron separately signed an MoU with NOC in Tripoli to evaluate the development and exploration potential onshore Libya. "Chevron is excited to enter Libya with the award of onshore Contract Area 106, which underscores our focus on

    2/11/26 9:15:00 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026

    Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-9843 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com. About Maravai M

    2/9/26 5:05:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026

    PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webc

    2/9/26 6:35:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $AXNX
    $BLD
    $CCCS
    $CLF
    SEC Filings

    View All

    SEC Form 10-K filed by Cleveland-Cliffs Inc.

    10-K - CLEVELAND-CLIFFS INC. (0000764065) (Filer)

    2/9/26 4:28:05 PM ET
    $CLF
    Metal Mining
    Basic Materials

    SEC Form SCHEDULE 13G filed by Myriad Genetics Inc.

    SCHEDULE 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    2/9/26 7:54:40 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cleveland-Cliffs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CLEVELAND-CLIFFS INC. (0000764065) (Filer)

    2/9/26 6:19:54 AM ET
    $CLF
    Metal Mining
    Basic Materials

    $AXNX
    $BLD
    $CCCS
    $CLF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $368,544 worth of shares (100,000 units at $3.69), increasing direct ownership by 181% to 155,123 units (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    12/9/25 4:36:29 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Brust Bernd bought $702,689 worth of shares (216,212 units at $3.25) (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    11/17/25 4:48:14 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Brust Bernd bought $809,010 worth of shares (250,559 units at $3.23) (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    11/13/25 5:27:45 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXNX
    $BLD
    $CCCS
    $CLF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    2/25/22 4:36:46 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    5/27/21 5:23:24 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXNX
    $BLD
    $CCCS
    $CLF
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Cleveland-Cliffs Appoints Edilson Camara to the Board of Directors

    Cleveland-Cliffs Inc. (NYSE:CLF) ("Cliffs") announced today that it has appointed Edilson Camara to its Board of Directors, effective immediately. Mr. Camara will serve on the Board's Compensation and Organization Committee, further strengthening Cliffs' leadership in talent, governance and global industrial strategy. Mr. Camara is Chief Executive Officer Emeritus at Egon Zehnder, a top global executive search and leadership advisory firm, and a senior partner in the firm's industrial practice group. During his tenure as CEO from 2018 to 2024, he led the firm's operations across 48 countries, with 69 offices, and 3,000 employees. Previously, Mr. Camara served as a long-standing member of

    11/12/25 7:00:00 AM ET
    $CLF
    Metal Mining
    Basic Materials

    $AXNX
    $BLD
    $CCCS
    $CLF
    Financials

    Live finance-specific insights

    View All

    Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026

    Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-9843 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com. About Maravai M

    2/9/26 5:05:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026

    PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webc

    2/9/26 6:35:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Cleveland-Cliffs Reports Fourth-Quarter and Full-Year 2025 Results

    Cleveland-Cliffs Inc. (NYSE:CLF) today reported fourth-quarter and full-year results for the period ended December 31, 2025. Highlights Fourth-quarter steel shipments of 3.8 million net tons Fourth-quarter GAAP net loss of $235 million, or $0.44 per diluted share Fourth-quarter adjusted net loss1 of $0.43 per diluted share Liquidity of $3.3 billion Fourth-Quarter Results Fourth-quarter 2025 consolidated revenues were $4.3 billion, consistent with prior-year fourth-quarter consolidated revenues of $4.3 billion. For the fourth quarter of 2025, the Company recorded a GAAP net loss of $235 million, or $0.44 per diluted share, with an adjusted net loss1 of $0.43 per diluted

    2/9/26 6:00:00 AM ET
    $CLF
    Metal Mining
    Basic Materials

    $AXNX
    $BLD
    $CCCS
    $CLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TopBuild Corp.

    SC 13G/A - TopBuild Corp (0001633931) (Subject)

    12/5/24 2:20:23 PM ET
    $BLD
    Engineering & Construction
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

    SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

    11/14/24 7:49:19 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

    SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

    11/14/24 4:16:31 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care